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A B S T R A C T
There is a growing interest in evaluating the effectiveness of enzyme replacement therapy (ERT) with elosulfase
alfa in patients with mucopolysaccharidosis type IVA (MPS-IVA) under real-world conditions. We present the
experience of seven pediatric MPS-IVA patients from the Spanish Morquio-A Early Access Program. Efficacy was
evaluated based on the distance walked in the 6-min walking test (6-MWT) and the 3-min-stair-climb-test (3-
MSCT) at baseline and after 8months of ERT treatment. Additionally, urinary glycosaminoglycans were mea-
sured, and a molecular analysis of a GALNS mutation was performed. The health-related quality of life was
evaluated using the EuroQoL (EQ)-5D-5 L.
The distance walked according to the 6-MWT ranged from 0 to 325m at baseline and increased to 12–300m
after 8 months with elosulfase alfa (the walked distance improved in all patients except one). An increase was
observed for the two patients who had to use a wheelchair. Improvements were also observed for the 3-MSCT in
four patients, whereas two patients showed no changes. Three patients showed an improvement in the EQ-VAS
score, whereas the scores of three patients remained stable. Regarding urinary glycosaminoglycans measure-
ments, an irregular response was observed. Our results showed overall improvement in endurance and func-
tionality after 8 months of elosulfase alfa treatment in a heterogeneous subset of MPS IVA patients with severe
clinical manifestations managed in a real-world setting.
1. Introduction
Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome,
OMIM 253000) is an autosomal recessive lysosomal storage disorder
(LSD) that was first described by Luis Morquio and James Brailsford in
1929 [1]. MPS IVA is caused by a deficiency of the N-acet-
ylgalactosamine-6-sulfate sulfatase (GALNS) enzyme, which leads to a
progressive accumulation of the glycosaminoglycans (GAGs) chon-
droitin-6-sulfate (C6S) and keratan sulfate (KS). The accumulation of
undegraded C6S and KS triggers progressive systemic skeletal dysplasia
in MPS IVA patients [2–5]. Significant non-skeletal manifestations, in-
cluding respiratory disease, spinal cord compression, cardiac disease,
impaired vision, hearing loss, and dental problems, have also been
described in these patients [6–8]. MPS IVA is more frequently asso-
ciated with severe and extensive skeletal manifestations than the other
MPS types. Specifically, hypermobility of the joints is a characteristic of
MPS IVA that distinguishes this disease from the other types. Further-
more, these patients exhibit no cognitive involvement [9]. In the mild
form, the symptoms can appear as late as the second decade of life [6],
and some patients can reach a normal stature [10–12]. In contrast,
patients with a severe form of MPS IVA may not survive beyond the
second or third decade of life.
The recent availability of enzyme replacement therapy (ERT) with
recombinant human GALNS (elosulfase alfa; Vimizin®; BioMarin
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Europe Ltd., London, UK) has provided systemic treatment for MPS IVA
when added to traditional symptom-based management. Elosulfase alfa
was shown to be effective and had an acceptable tolerability profile in a
phase 1/2, open-label, dose-escalation study and a pivotal 24-week,
randomized, double-blind, placebo-controlled clinical trial [13,14],
which led to marketing authorization for elosulfase alfa as a treatment
for MPS IVA by FDA in February 2014 and by the European Medicines
Agency in April 2014. Nevertheless, patients with MPS IVA have very
heterogeneous clinical phenotypes due to the multiple systems affected
by the disorder, and no studies have evaluated how this therapy works
in a real-world setting. The present report describes our experience
using elosulfase alfa treatment of seven pediatric patients from the
Spanish Morquio A Early Access Program (MOR-EAP).
2. Materials and methods
The MOR-EAP started in 2014 as a compassionate use program to
provide access to elosulfase alfa for patients with MPS IVA after ap-
proval from the European Medicines Agency (April 28, 2014) while
they waited for inclusion in the Spanish public health system. The pa-
tient inclusion criteria were similar to the criteria described for the
pivotal clinical trial [14]. Individuals had a confirmed diagnosis of MPS
IVA as documented by GALNS molecular genetic testing. The exclusion
criteria included prior hematopoietic stem cell transplantation (HSCT)
or a concurrent disease or condition that would interfere with ERT. The
MOR-EAP was undertaken according to the Spanish regulations on
access to medicines under special conditions [15]. Written informed
consent was obtained from the parents or a legally authorized re-
presentative together with the child's assent.
All patients included in the program received elosulfase alfa
(2.0 mg/kg/week) and were pre-treated with an antihistamine drug to
reduce the risk of infusion-related adverse reactions. During the pro-
gram, the following efficacy information was collected: the distance
walked in the 6-MWT [16] and the 3-MSCT [17]. Additionally, re-
spiratory function tests were performed according to published Eur-
opean Respiratory Society and Spanish Pediatric Pneumology Associa-
tion guidelines [18], including the forced vital capacity (FVC), forced
expiratory volume in one second (FEV1) and FEV1/FVC ratio. The
clinical examinations also included anthropometric measurements
(weight, length and body mass index [BMI]), audiometry measure-
ments, vital signs, electrocardiograms and echocardiograms, an oph-
thalmological examination, magnetic resonance imaging of the brain
and spine, and radiographs of the lower extremities and the spine.
Total urinary GAGs were measured according to an improved di-
methylene blue (DMB) test. This method involved assaying GAGs in the
DMB dye followed by a spectrophotometric analysis of the resulting
complex. The normal values for this method depend on age [19]. Mo-
lecular analysis of GALNS mutations was performed as previously de-
scribed [20].
The health-related quality of life (HRQoL) was measured with the
EuroQoL (EQ)-5D-5L questionnaire [21]. We use the EQ-5D-5L ques-
tionnaire, as recommended by the international guidelines for the
management and treatment of MPS IVA [22]. This questionnaire is a
simple but complete self-administered measure of the HRQoL for a wide
range of health conditions that has been translated into 106 languages
[21]. This generic standardized tool comprises five dimensions (mobi-
lity, self-care, usual activities, pain/discomfort and anxiety/depres-
sion). The results are presented as the EQ Visual Analog Scale (VAS)
score as a measure of the overall self-rated health status, for which the
data range from 100 (the best state one can imagine) to 0 (the worst
state one can imagine). Adverse reactions were also recorded during the
8-month period.
3. Results
This early access program included seven patients aged 7–17 years.
The clinical features of these patients before they began elosulfase alfa
treatment are presented in Table 1. The evolution of endurance was
evaluated with the 6-MWT and the 3-MSCT, which are represented in
Figs. 1 and 2, respectively. An improvement in the walking distance (6-
MWT) was observed after 8months of treatment with elosulfase alfa in
all but one patient (Fig. 1).
Improvements were also observed in the 3-MSCT in four subjects;
whereas two subjects showed no change and one subject had no data
available (Fig. 2). A marked improvement was observed in patient #6,
whose scores nearly doubled on both tests. Patients #4 and #5 were not
independently mobile and had to use a wheelchair (baseline 6-MWT
distances of 0 and 20m, respectively). However, these patients also
showed improvement in their walking distances after 8months on
elosulfase alfa (6-MWT distances of 24 and 32m, respectively; Fig. 1).
Information on the anthropometric characteristics, clinical assess-
ments, urine GAG levels and HRQoL evaluation results at baseline and
after 8months of ERT is shown in Table 1. Four patients had urine
GAGs measured at baseline and at 8months; of those patients, three
showed a reduction in GAGs at the end of the follow-up period
(Table 1). During this period, small variations in respiratory function
were observed after 8months of treatment with elosulfase alfa
(Table 1). Thus, five patients showed improvements in their FVC ran-
ging from a 4% to 19% increase from baseline, one patient had an
unchanged FVC and another patient had a reduced FVC. The cardiac
function evaluation showed no changes with the exception of two pa-
tients who showed normalization of their intraventricular septum hy-
pertrophy. The magnetic resonance imaging (MRI) findings also
# 1 # 2 # 3 # 4 # 5 # 6 # 7
Baseline 226 237 282 0 20 200 325
















Fig. 1. Assessment of endurance according to the 6-min walking test (6-MWT)
at baseline and after 8months of elosulfase alfa therapy in the Morquio A Early
Access Program (MOR-EAP).
A 0 score was given to patients who did not walk.
Baseline 0 21 40 0 3 17 23
8 months 0 21 60 0 7 40 33








Fig. 2. Assessment of endurance according to the 3-min-stair-climb-test (3-
MSCT) at baseline and after 8months of elosulfase alfa therapy in the Morquio
A Early Access Program (MOR-EAP).
3-MSCT: Results are given as stairs/min.
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remained unchanged, and similar results were obtained for the hearing
and ophthalmologic evaluations. The evolution of the quality of life as
measured with the EQ-5D-5 L VAS score is presented in Table 1. Pa-
tients #1, #2 and #7 showed an improvement in their HRQoL scores
after 8months of treatment, whereas three patients remained stable.
The HRQoL was not evaluated in one patient. In the pre-pubertal pa-
tients (< 9 and 10 years old for girls and boys, respectively), the range
of growth was 0.8 to 4 cm. The elosulfase alfa infusion was well tol-
erated, and no serious adverse events were reported. No treatment
disruption or surgical intervention was required during the study.
4. Discussion
This early access program in a group of highly heterogeneous pa-
tients with MPS IVA showed that elosulfase alfa provided benefits to the
patients in terms of endurance and functionality in a real-world setting
that were similar to the benefits reported in the randomized pivotal
trial [23].
The data available from the 7 MOR-EAP patients at baseline support
the findings in natural history studies that describe this rare disease as a
progressive, multi-organ/systemic, heterogeneous pathology
[6,7,24–26]. Most of the cases described in the present study showed
not only a variety of clinical manifestations in the musculoskeletal
system (several forms of stenosis –segmental and multisegmental-,
dysplasia and myelopathy) but also breathing difficulties, cardiac valve
disease, impaired vision (corneal opacity) and hearing loss. Several
factors may have determined the severity of the disease, and although
no definition has been currently proposed, growth and final height are
commonly accepted as indicators of disease severity in MPS IVA
[27,28]. Patients in this case series were classified as severe MPS IVA
with the exception of patient #3, who had a less severe manifestation of
the disease. Overall, we believe that this report may be of interest to
clinicians who need information in addition to the data from ex-
planatory randomized trials regarding the effects of elosulfase alfa
therapy under real-world conditions.
The 6-MWT and 3-MSCT results revealed an important impairment
of endurance and mobility in this MPS IVA population regardless of age.
The distance walked according to the 6-MWT ranged from 0 to 325m at
baseline. The lower limit for healthy individuals 4–16 years of age
ranges from 470 to 664m [29,30]. Several studies have shown similar
scores at baseline [7,24–26], but the natural course of the disease in-
volves decreasing endurance as patients age [22]. The administration of
elosulfase alfa to patients with MPS IVA in this 8-month program led to
improvements in walking distances in all but one patient. The im-
provements ranged from 12 to 300m, and in three patients the im-
provement was above the mean increase of 37m reported in the pivotal
trial [23]. Interestingly, two patients who showed a walking distance in
the 6-MWT below 30m (patients #4 and #5), which was an exclusion
criterion in the pivotal trial for elosulfase alfa [23], also experienced
improvements in walking distance (24 and 12m). Based on an ex-
ploratory subgroup analysis, we hypothesized that elosulfase alfa
treatment might be more effective in patients with more severe disease
at baseline (i.e., in patients who could walk a distance ≤200m)
[23,31]. The results of this case series do not support that hypothesis,
because the changes in the walking distance in three of the five subjects
who walked>200m at baseline were above the walking distance in
that subgroup from that exploratory analysis (38, 59 and 300m vs. a
mean of 25m). In contrast to the pivotal trial, which found a trivial
improvement in the 3-MSCT (i.e., +1.1 stairs/min) [23], we found a
relevant improvement in the 3-MSCT in four patients (three patients
had an increase of> 10 stairs/min), including one patient who was
unable to walk a distance>30m in the 6-MWT but exhibited an in-
crease of 4 stairs/min. The results of the 3-MSCT were remarkable,
especially considering that studies hypothesized that this test might not
be suitable for patients with MPS IVA because these patients had severe
skeletal dysplasia, short stature and joint involvement that considerably
limited their ability to climb stairs [26]. Patient #7, who showed a
slight decrease in the walking distance in the 6-MWT, experienced an
improvement in the 3-MSCT. This lack of correlation between the 6-
MWT and 3-MSCT results was also found in the pivotal trial with elo-
sulfase alfa, in which the performance in the 6-MWT did not translate to
better performance in the 3-MSCT [23,31]. The 6MWT measures the
integrated function of at least 3 separate organ systems that are affected
by MPS IV A: the respiratory, cardiovascular, and musculoskeletal
systems. The mechanism of improvement is not well established but
could be related to the improvement of respiratory function and pain.
Reduced respiratory function was also observed in our series at
baseline with limited volumes in FVC for all the MOR-EAP individuals.
Treatment with elosulfase alfa led to a slight improvement in re-
spiratory function for most patients. These results were also consistent
with the results of the pivotal trial, which showed a slight increase in
the FVC and forced expiratory volume in 1 s (FEV1) after a follow-up
period of 24months [23]. However, the observation period in our series
may have been too short to evaluate the impact of elosulfase alfa on
respiratory functions, because the extended study period of the pivotal
trial with elosulfase alfa showed that the percentage change from
baseline in the FVC increased from<4% at 24weeks to 7–8% at 72 and
120weeks [32]. In healthy children, the longitudinal improvement in
pulmonary function was found to be age-dependent, with the greatest
increase occurring during puberty [26]. Height increase and thoracic
enlargement most likely facilitate respiratory functions and therefore
increase the FVC and MVV volumes in patients< 14 years old [26].
However, the older patients in our series (#6 and #7), reached their
highest FVC and FEV volumes. The more impaired respiratory func-
tionality was observed in patient #1, who was only 7 years old.
Nevertheless, individuals #2 and #3 were also 7 years old, and their
FVC and FEV1 volumes were greater and similar to each other.
Cardiovascular involvement in MPS IVA patients can lead to early
mortality. Thus, rapid intervention may be life-saving [33]. We did not
find relevant changes in the echocardiograms after elosulfase alfa
therapy. Similarly, the ophthalmological and audiometric evaluations
were unchanged under ERT at 8months. The results of urinary GAGs
were difficult to analyze. On one hand, not all patients with MPS IVA
had elevated GAG levels at diagnosis. On the other hand, the levels may
decrease naturally with age, which may explain the low baseline levels
found in patients #6 and #7 [22]. Almost all studies use this measure,
but no data are available to support its usefulness in the clinical man-
agement of MPS IVA [34]. It is possible that measurement of urinary
keratan sulfate instead of total GAGs, and a more homogeneous popu-
lation would give more consistent results.
For a debilitating disease such as MPS IVA, evaluating a patient's
HRQoL is of paramount importance. Reduced endurance or mobility,
difficulties in activities of daily living, dependence on caregivers, fre-
quent surgical interventions, pain and fatigue are factors that are fre-
quently reported by patients with MPS IVA [7,8]. The global EQ-VAS
scores ranged from 45 to 60 at baseline with the exception of patient
#2, who had a more severe condition. However, this patient reported a
clinically meaningful improvement after 8months of elosulfase alfa
therapy. Of the 5 remaining evaluated patients, 2 showed improvement
in the HRQoL and 3 showed no changes, including the two patients with
the most severe mobility problems (patients #4 and #5). There is the
possibility of improvement of some clinical variables by motivation or
training.
In conclusion, there is a growing interest in the availability of real-
world data from patients with rare diseases [35], including MPS IVA
[36]. This case series provided a first look into the effectiveness of
elosulfase alfa treatment in patients with MPS IVA under real-world
conditions. Overall, our results showed improvements in endurance and
functionality with elosulfase alfa that were at least similar to the im-
provements reported in the explanatory setting of the pivotal trial, in-
cluding the results from two patients who were markedly affected by
mobility problems (i.e., patients excluded from the pivotal trial) who
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exhibited a modest but relevant improvement in endurance and showed
no changes in their HRQoL. However, in addition to the limitations
inherent to small case series, more information is needed on the impact
of elosulfase alfa on other outcomes that are relevant to the patients,
such as fatigue, joint stiffness and pain [31]. Therefore, our results
should be confirmed with long-term multidimensional data from re-
gistries.
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